Caring Brands (NASDAQ:CABR) Shares Down 1.8% – Here’s What Happened

Caring Brands, Inc. (NASDAQ:CABR)’s share price traded down 1.8% during mid-day trading on Tuesday . The company traded as low as $1.34 and last traded at $1.34. Approximately 90,915 shares changed hands during trading, an increase of 52% from the average daily volume of 59,778 shares. The stock had previously closed at $1.3650.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Caring Brands from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 11th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Caring Brands Trading Down 1.8%

The company has a market cap of $12.18 million and a price-to-earnings ratio of -2.09. The company has a current ratio of 5.66, a quick ratio of 5.62 and a debt-to-equity ratio of 0.03. The company’s 50 day moving average price is $1.21.

Caring Brands (NASDAQ:CABR) last released its earnings results on Tuesday, May 12th. The company reported ($0.27) earnings per share for the quarter.

Institutional Investors Weigh In On Caring Brands

An institutional investor recently bought a new stake in Caring Brands stock. Jane Street Group LLC bought a new position in shares of Caring Brands, Inc. (NASDAQ:CABR) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.25% of Caring Brands at the end of the most recent quarter.

Caring Brands Company Profile

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.